ACCD 📈 Accolade - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00437E1029
ACCD: Healthcare, Technology, Benefits, Advocacy, Navigation, Consulting
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington. Web URL: https://www.accolade.com
Additional Sources for ACCD Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACCD Stock Overview
Market Cap in USD | 292m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2020-07-02 |
ACCD Stock Ratings
Growth 5y | -0.29% |
Fundamental | -29.0% |
Dividend | - |
Rel. Strength Industry | -1418 |
Analysts | 4.36/5 |
Fair Price Momentum | 1.81 USD |
Fair Price DCF | - |
ACCD Dividends
No Dividends PaidACCD Growth Ratios
Growth Correlation 3m | -37.1% |
Growth Correlation 12m | -91.5% |
Growth Correlation 5y | -83.6% |
CAGR 5y | 50.81% |
CAGR/Mean DD 5y | 0.82 |
Sharpe Ratio 12m | -1.19 |
Alpha | -118.43 |
Beta | 2.03 |
Volatility | 55.72% |
Current Volume | 2043.6k |
Average Volume 20d | 1102.4k |
What is the price of ACCD stocks?
As of December 22, 2024, the stock is trading at USD 3.48 with a total of 2,043,560 shares traded.
Over the past week, the price has changed by -0.29%, over one month by -2.25%, over three months by -12.34% and over the past year by -67.84%.
As of December 22, 2024, the stock is trading at USD 3.48 with a total of 2,043,560 shares traded.
Over the past week, the price has changed by -0.29%, over one month by -2.25%, over three months by -12.34% and over the past year by -67.84%.
Is Accolade a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Accolade (NASDAQ:ACCD) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.97 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACCD as of December 2024 is 1.81. This means that ACCD is currently overvalued and has a potential downside of -47.99%.
Probably not. Based on ValueRay Fundamental Analyses, Accolade (NASDAQ:ACCD) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.97 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACCD as of December 2024 is 1.81. This means that ACCD is currently overvalued and has a potential downside of -47.99%.
Is ACCD a buy, sell or hold?
Accolade has received a consensus analysts rating of 4.36. Therefor, it is recommend to buy ACCD.
Accolade has received a consensus analysts rating of 4.36. Therefor, it is recommend to buy ACCD.
- Strong Buy: 8
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecast for ACCD stock price target?
According to ValueRays Forecast Model, ACCD Accolade will be worth about 2 in December 2025. The stock is currently trading at 3.48. This means that the stock has a potential downside of -42.82%.
According to ValueRays Forecast Model, ACCD Accolade will be worth about 2 in December 2025. The stock is currently trading at 3.48. This means that the stock has a potential downside of -42.82%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 7.3 | 108.6% |
Analysts Target Price | 14.8 | 324.4% |
ValueRay Target Price | 2 | -42.8% |